Xilio Therapeutics XLO Cash Flow Statement (2020-2026)

NASDAQ XLO
$8.99 +0.02 (+0.28%)
As of: Sep 10, 2026 · 1:21 PM EDT
Reported Financials

Xilio Therapeutics Quarterly Cash Flow Statement

Periods 24 quarters
Latest Jun 2026

Xilio Therapeutics reported cash from operations of -$18.76M and free cash flow of -$18.78M for the quarter ended Jun 2026, down 29.6% year over year. This cash flow statement covers 24 quarters of results from Sep 2020 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow Statement Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Operating Activities
Net Income
-16.25M-19.73M-21.35M-24.55M-20.21M-23.17M-23.53M-20.12M-17.36M-18.13M-17.49M-14.70M-14.76M-13.63M-13.85M-14.37M-1.93M-11.84M-14.11M-3.49M
Share-based CompensationStock Comp.
3.39M2.07M4.95M5.18M5.00M1.81M2.06M5.98M7.82M1.93M7.58M8.04M8.01M1.52M10.86M11.45M11.51M2.93M2.77M2.45M
Gains from Investment SecuritiesGains Investment
0.05M15.38M-21.27M-3.30M3.94M
Cash from OperationsCash from Ops.
-20.72M-17.16M-20.84M-16.76M-19.91M-18.22M-25.25M-16.57M-13.37M-13.43M-10.50M19.95M-13.67M-14.16M28.98M-14.48M-17.50M-2.00M-22.34M-18.76M
Depreciation, Depletion & Amortization
Depreciation & Amortization (CF)Dep. & Amort.
0.38M0.39M0.44M0.45M0.47M0.49M0.50M0.49M0.46M0.45M0.44M0.45M0.38M0.38M0.50M0.38M0.34M0.32M0.34M0.33M
Change in Working Capital
Change in ReceivablesChange Receivables
30.00M-12.50M-5.00M6.00M
Change in Account PayablesChange Payables
-3.55M-1.19M-0.82M-0.40M0.24M1.46M-1.36M-0.81M0.54M-0.44M-0.30M0.51M-0.28M1.60M-0.59M2.11M-1.80M0.43M-1.68M1.26M
Change in Accured ExpensesChange Accured Exp.
-0.30M0.84M-1.43M4.63M-3.09M1.47M-3.87M0.66M2.28M1.10M-2.50M1.25M-0.21M-0.09M-6.38M1.16M3.31M0.93M-1.54M-1.45M
Investing Activities
Capital ExpendituresCapex
0.11M0.38M0.25M0.77M0.33M0.51M0.31M0.18M0.02M0.01M0.01M0.29M0.13M0.10M0.56M0.02M
Cash from Investing ActivitiesCash from Investing
-0.11M-0.38M-0.25M-0.77M-0.33M-0.51M-0.17M-0.32M-0.01M-0.01M-0.02M-0.40M-0.10M-0.56M-0.02M
Financing Activities
Other financing activitiesOther financing
0.01M0.24M0.02M0.05M4.31M-14.57M0.03M0.01M0.04M35.79M0.00M0.04M
Cash from Financing ActivitiesCash from Financing
0.30M115.83M-0.01M-0.02M-0.02M-0.02M-1.69M-0.99M-2.24M-1.63M0.95M20.04M-0.00M8.20M4.83M47.36M-0.28M35.87M35.71M4.49M
Change in Capital Stock
Net Shares Issued and RepurchasedNet Shares Issued
3.79M0.87M1.75M1.53M3.74M0.63M2.58M2.85M2.57M0.03M
Net Equity Issued and RepurchasedNet Equity Issued
0.00M2.02M45.02M-0.03M47.00M
Additional items
Change in Cash
-20.53M98.29M-21.09M-17.55M-20.26M-18.75M-27.11M-17.88M-15.61M-15.06M-9.55M39.98M-13.68M-5.96M33.79M32.48M-17.78M33.77M12.81M-14.29M
Free Cash FlowFCF
-20.83M-17.54M-21.09M-17.53M-20.24M-18.73M-25.56M-16.75M-13.37M-13.43M-10.52M19.95M-13.68M-14.16M28.69M-14.61M-17.50M-2.09M-22.90M-18.78M
Net Cash FlowNCF
-20.53M98.29M-21.09M-17.55M-20.26M-18.75M-27.11M-17.88M-15.61M-15.06M-9.55M40.00M-13.68M-5.96M33.79M32.48M-17.78M33.77M12.81M-14.29M